(Reuters) – Wall Street looked set to start the week on an upbeat note on Monday, as investors hoped for progress in resolving the U.S.-China trade war, but a fall in Boeing’s shares kept a lid on early gains.
FILE PHOTO: Traders work on the floor at the New York Stock Exchange (NYSE) in New York, U.S., October 18, 2019. REUTERS/Brendan McDermid
Chinese Vice Premier Liu He said on Saturday that Beijing would work with Washington to address core concerns, adding to optimism from President Donald Trump’s comments on Friday that he expected a trade deal to be signed by mid-November.
However, Boeing Co (BA.N) was set to extend a slide from the previous session as two brokerages downgraded the stock after leaked messages from a former test pilot showed he might have unintentionally misled regulators about the safety of the grounded 737 MAX jet.
Shares of the planemaker fell nearly 2%.
Wall Street has been steadily recovering after a rough start to the month on signs of progress in talks between the world’s two largest economies.
At 7:19 a.m. ET, Dow e-minis 1YMcv1 were up 29 points, or 0.11%. S&P 500 e-minis EScv1 were up 6.25 points, or 0.21% and Nasdaq 100 e-minis NQcv1 were up 21 points, or 0.27%.
Investors are now gearing up for another batch of reports after a strong start to the third-quarter earnings season last week, with big technology companies including Microsoft Corp (MSFT.O) and Intel Corp (INTC.O) set to report their earnings this week.
Analysts project S&P 500 earnings dropping 3.1%, compared with a year earlier, marking the first contraction since 2016, according to Refinitiv data.
But of the 73 companies that have reported results so far, nearly 84% have topped analysts’ estimates.
Oilfield services provider Halliburton Co (HAL.N) dipped 0.4% after reporting a 32% slump in third-quarter profit, hit by a slowdown in shale drilling in North America, its biggest market.
Drug distributors Cardinal Health Inc (CAH.N) fell 3% and McKesson Corp (MCK.N) slipped 4.1%, ahead of a trial over the U.S. opioid epidemic after drug companies and local governments failed to reach a settlement on Friday.
Reporting by Shreyashi Sanyal in Bengaluru; Editing by Anil D’Silva